In addition to its clinical development pipeline focusing on CMV, Microbiotix has innovative antibacterial and antiviral discovery programs in areas with significant unmet medical needs, including:
Gram-Negative Bacterial Infections
Microbiotix has a small molecule R&D program targeting the Type III Secretion System (T3SS) of Pseudomonas aeruginosa, an opportunistic gram-negative pathogen. P. aeruginosa's T3SS is a virulence factor that plays a major role in ventilator-associated pneumonia (VAP), where current antibiotic treatment strategies exhibit unacceptably high failure rates (up to 18%). To address this critical medical need, T3SS inhibitors will be administered therapeutically and prophylactically in combination with anti-pseudomonal agents to enhance bacterial eradication by potentiating the host's innate immune system and improving the antibacterial activity of co-administered antibiotics. Other applications of T3SS inhibitors will include prevention or treatment of additional diseases in which T3SS plays a major role, e.g., P. aeruginosa bacteremia, a frequent sequela of VAP that contributes to the high mortality rate, and P. aeruginosa wound and urinary tract infections (UTI). Microbiotix has identified and is developing a novel series of small molecule T3SS inhibitors.